Leukemia Survival Rate
The overall leukemia survival rate has more than quadrupled since 1960. Since that time, researchers have made major strides in identifying effective treatments for leukemia, and scientists continue to make significant progress in understanding the underlying causes of the condition. As a result, many people who have been diagnosed with leukemia are living longer, higher-quality lives.
When learning about the leukemia survival rate, it’s important to keep in mind the specific nature of this data. Rather than being a conclusive predictor, the leukemia survival rate is nothing more than a collective descriptor of the experiences of a large number of patients who were diagnosed and treated several years ago. Since the time that this information was collected and analyzed, new and better ways to prevent, diagnose and treat the condition have been discovered and implemented. In other words, a newly diagnosed leukemia patient can benefit from medical advances that weren’t available to the patients whose experiences factored into the most recently published survival rate, and therefore can potentially experience a better outcome that a similarly situated patient of only a few years ago.
Of course, each patient is unique, and many factors can contribute to the leukemia survival rate. Those factors include:
- The patient’s age at the time of diagnosis
- Whether the cancer cells have spread to the brain or spinal cord
- Whether the leukemia is a recurrence of a condition for which the patient was previously treated
- The patient’s response to treatment
- The type of leukemia a person has been diagnosed with
As the knowledge base continue to grow, the leukemia survival rate can be expected to improve. Positioned firmly at the forefront of leukemia research is Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida. In addition to fellowship-trained surgeons – some of the best in the nation – Moffitt provides patients with access to multispecialty cancer treatment, including an active clinical trial program.